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The estimated prevalence of being overweight and obese in US
women aged 40–79 years has increased from approximately
42% in 1988–1991 to 67% in 1999–2000 [1]. While previous
studies have shown that the risk of venous thrombosis (VT)
among overweight or obese individuals is increased compared
with normal weight individuals [2–6], the risk associated with
modest levels of excess weight and with below-normal weight
has not been explored in detail. Additionally, little is known
about the role of postmenopausal hormone therapy, a known
risk factor for VT [7,8], in modifying the association between
excess weight and VT risk. Using data from a large, popula-
tion-based case–control study, we examined (i) whether an
increased body mass index (BMI), a proxy for adiposity,
increased the risk of VT among postmenopausal women; and
(ii) whether hormone therapy modified this association. We
also explored the association between below-normal BMI and
VT risk.
This research was part of an on-going, case–control study of
risk factors for cardiovascular disease at Group Health
Cooperative (GHC), a health-maintenance organization in
western Washington State [9]. Case subjects were postmeno-
pausal female GHC members, between the ages of 30 and
89 years, who had a first deep vein thrombosis (DVT) or fatal
or non-fatal first pulmonary embolism (PE) diagnosed between
January 1, 1995 and December 31, 2002. Potential cases were
identified using hospital discharge diagnosis codes for inpatient
events and GHC outpatient pharmacy files indicating use of
low-molecular weight heparin or the use of the GHC outpa-
tient anticoagulation treatment programmes for non-hospital-
ized events. Ninety-two percent of the VT events were
objectively confirmed with imaging. The date of the VT served
as an index date prior to which information on weight and
other exposures was ascertained. Control subjects were a
random sample of postmenopausal female GHC members,
identified from the GHC enrollment files, with no history of
VT. For control subjects, the index date was a randomly
chosen date within the calendar year for which they were
selected as a control.
Data were collected from a review of the GHC outpatient
medical record, a telephone interview, the GHC computerized
pharmacy data base, inpatient and outpatient diagnosis files,
and the GHC cancer registry. Information on variables of
interest was restricted to dates prior to the index date for both
cases and control subjects.
Unconditional logistic regression was used to estimate odds
ratios (OR) and 95% confidence intervals (CI). BMI was
categorized as follows: < 18.5 kg m)2 (underweight), 18.5–
24.9 kg m)2 (normal weight), 25.0–29.9 kg m)2 (overweight),
30.0–34.9 kg m)2 (class I obese), 35.0–39.9 kg m)2 (class II
obese), 40.0–44.9 kg m)2 (class IIIa obese), and
45.0+ kg m)2 (class IIIb obese). A test for trend was
performed across BMI categories. BMI was also modeled as
a continuous term and departure from linearity was investi-
gated with the addition of a quadratic term. All multivariate
models were adjusted for the matching variables age, calendar
year, and hypertension status. Potential confounding variables
considered in the models included hospitalization or major
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fracture, malignancy, use of hormone therapy, and weekly
physical activity. Whether the association of BMI with VT
risk was modified by hormone therapy use was assessed by
introducing cross-product terms into the multivariate model;
significance was assessed using the likelihood ratio test.
Polytomous logistic regression was used to assess whether
the associations between BMI and the different outcomes of
PE and DVT differed significantly from one another. Data
were also stratified by subject characteristics including age
(< 70 vs. 70+ years), malignancy and whether or not the VT
event was idiopathic. Events were classified as idiopathic if
they occurred in the absence of a recent cancer diagnosis,
hospitalization, fracture, or while the woman was not using
hormone therapy, a known risk factor for VT.
A total of 913 subjects with a first VT (59% with DVT only,
27%with PE only and 14%with both DVT and PE) and 2834
control subjects were identified. Cases were more likely to be
white (92% vs. 87%). Mean age for cases was 71.0 years and
for control subjects 69.6 years. Consistent with known risk
factors for VT, higher proportions of cases than control
subjects had malignancies (27% vs. 12%), hospitalizations
(36% vs. 3%) and fractures (5% vs. 1%) within 3 months
before the index date. Current hormone therapy use did not
differ between cases and control subjects (34% vs. 34%).
Mean (SD) BMI was 28.8 kg m)2 (7.8) in cases and
27.9 kg m)2 (6.4) in control subjects. BMI was associated with
an increased risk of VT inmultivariate models after adjustment
for the matching variables, recent hospitalizations and malig-
nancies (Table 1). Compared with subjects with a normal
weight (18.5–24.9 kg m)2), subjects in higher categories of
BMIwere at higher risk of VT. Risk estimates increased in each
successively higher BMI group (P for trend < 0.001). In a
model where BMIwasmodeled as a continuous variable rather
than in categories, among those with a BMI ‡ 18.5 kg m)2, a
standard deviation increase in BMI (6.4 kg m)2) was associ-
ated with an odds ratio of 1.35 (95%CI 1.24, 1.48) and a 1-unit
increase in BMIwas associated with an odds ratio of 1.05 (95%
CI 1.03, 1.06) in adjusted analyses. No departure from linear
trend was detected when a squared BMI term was added to the
model (P ¼ 0.45).
Adjustment for hormone therapy use, major fractures and
weekly physical activity did not change risk estimates. Overall,
BMI < 18.5 kg m)2 was not associated with risk compared
with normal weight.
When we examined the joint association of BMI and current
hormone therapy use with the risk of VT, we found that the
risk of VT increased with increasing BMI ‡ 18.5 kg m)2 in
both users (OR per standard deviation increase of BMI 1.34;
95%CI 1.16, 1.55) and non-users (OR 1.37; 95%CI 1.23, 1.53)
of hormone therapy (P-value for interaction ¼ 0.69) and we
detected no departures from a linear trend in either group
(Table 1). In analyses stratified by estrogen-type, a one
standard deviation increase in BMI was associated with a
35% increase in VT risk in conjugated equine estrogen users
(OR 1.35; 95% CI 1.12–1.62) and a 22% increase in esterified
estrogen users (OR 1.22; 95% CI 0.99–1.51). There was no
evidence of an interaction between BMI and estrogen of either
type (P-value for interaction ¼ 0.29 and 0.63, respectively).
With the exception of the 25.0–29.9 BMI category, risk
differences between therapy users and non-users across BMI
categories were not statistically significant. The risk of VT
among underweight women compared with those with
normal weight was elevated among hormone non-users (OR
1.80; 95% CI 1.02–3.23), whereas the risk was not elevated
among users (OR 0.75; 95% CI 0.32–1.72; P-value for
interaction ¼ 0.08).
When the outcomes were stratified by DVT vs. any PE, a
standard deviation increase in BMI was associated with higher
risk of both DVT (OR 1.21; 95% CI 1.08, 1.35) and PE (OR
1.53; 95% CI 1.36, 1.71). This association differed significantly
between the two outcomes (P < 0.001). The BMI-risk
association for idiopathic (OR 1.58; 95% CI 1.39, 1.80) vs.
non-idiopathic (OR 1.21; 95% CI 1.09, 1.35) events also
differed significantly (P < 0.001). We found no evidence that
the association between BMI and VT risk varied with age and
presence of malignancy.
Table 1 Association of body mass index (BMI) with risk of incident venous thrombosis
BMI (kg m)2)
CATEGORICAL
Cases,
n (%)
Controls,
n (%)
Adjusted OR*
(95% CI)
No hormone therapy Hormone therapy
n
(case/control)
Adjusted OR*
(95% CI)
n
(case/control)
Adjusted OR*
(95% CI)
< 18.5 45 (4.9) 66 (2.3) 1.40 (0.86, 2.26) 35/44 1.81 (1.02, 3.23) 10/22 0.75 (0.32, 1.72)
18.5–24.9 263 (28.8) 943 (33.3) 1.00 (Referent) 183/609 1.00 (Referent) 80/334 1.17 (0.82, 1.66)
25.0–29.9 293 (32.1) 964 (34.0) 1.48 (1.18, 1.85) 192/647 1.26 (0.95, 1.67) 101/317 2.39 (1.72, 3.33)
30.0–34.9 152 (16.7) 509 (18.0) 1.49 (1.13, 1.95) 95/340 1.45 (1.03, 2.04) 57/169 1.89 (1.26, 2.84)
35.0–39.9 85 (9.3) 207 (7.3) 2.41 (1.71, 3.39) 53/133 2.36 (1.53, 3.64) 32/74 3.17 (1.89, 5.32)
40.0–44.9 32 (3.5) 91 (3.2) 2.20 (1.39, 3.45) 20/52 2.57 (1.42, 4.64) 12/19 2.19 (1.09, 4.40)
> 45.0 43 (4.7) 54 (1.9) 3.94 (2.32, 6.70) 28/40 3.88 (2.01, 7.51) 15/14 5.89 (2.46, 14.11)
BMI (kg m)2)
CONTINUOUS
Cases,
n (%)
Controls,
n (%)
OR per SD increase
in BMI (95% CI)
n
(case/control)
OR per SD increase
in BMI (95% CI)
n
(case/control)
OR per SD increase
in BMI (95% CI)
‡ 18.5 868 (95.1) 2768 (97.7) 1.35 (1.24, 1.48) 571/1821 1.37 (1.23, 1.53) 297/927 1.34 (1.16, 1.55)
SD, standard deviation; CI, confidence interval. *Adjusted for the matching factors age, calendar year and hypertension status, and for recent
hospitalizations and malignancy. P-trend < 0.001 (for BMI ‡ 18.5 kg m)2). One standard deviation of BMI is 6.4 kg m)2.
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In this large population-based, case–control study of post-
menopausal women, increasing BMI was positively and
linearly associated with a higher risk of VT. Our results are
similar to findings from several population-based studies that
have considered the risk of VT among individuals with
increased BMI [3–5], but our results demonstrate that the
BMI-risk association is best described as linear across the range
of normal weights and above.
The use of exogenous hormones did not appear to modify
the BMI–VT relationship in women with normal and above
body weight. Several studies, including one utilizing the same
source population as the present study, have demonstrated an
increased risk of VT among users of hormone therapy
compared with non-users, particularly among users of conju-
gated equine estrogen [7,8,10,11]. We did not find, however,
consistent evidence across BMI categories that hormone use
modified the BMI-VT relationship. For both users and non-
users of hormone therapy, the association between BMI and
VT risk was found to be linear. Our findings in postmenopausal
women are not consistent with evidence from premenopausal
women where VT risk increased for those exposed to oral
contraceptives and obesity beyond what would have been
expected by either factor alone [4]. Others have also not
found synergistic risk associations between hormones and
either age or BMI in postmenopausal women [6].
There are a number of biological mechanisms that may
mediate the increased risk of VT observed among individuals
with a higher than normal BMI.As BMI increases, a significant
increase in procoagulant factors associated with VT risk has
been observed [12,13]. Estrogen production, which is directly
correlated with body weight in postmenopausal women [14],
has also been shown to increase procoagulant components of
the hemostatic system [15]. However, a recent study suggested
that several coagulation factors, including factors VIII and X
and fibrinogen, were not in the putative causal pathway
between BMI and VT risk [4]. Stasis associated with a
sedentary lifestyle is also a possible cause of increased risk of
VT; however, adjustment for leisure-time physical activity did
not change our results.
This population-based case–control study found that the risk
of VT increased linearly with BMI in postmenopausal women
with normal and above body weights and that the association
did not differ by current use of hormone therapy. Our findings
support recent public health messages about the importance of
maintaining a normal body weight as even modest amounts of
excess body weight may be associated with increased VT risk.
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